Entrada Therapeutics (TRDA) Operating Margin (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Operating Margin of 4834.63% for Q1 2026, down 472864.0% year-over-year from N/an in Q1 2025, and down 48.79% quarter-over-quarter from 3249.27% in Q4 2025.
Entrada Therapeutics (TRDA) Operating Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' Operating Margin history runs 4 years deep, the most recent figure standing at 4834.63% for Q1 2026.
- In Q1 2026, Operating Margin fell 472864.0% year-over-year to 4834.63%; the TTM figure through Mar 2026 stood at 3109.29% (down 311167.0% YoY), while the FY2025 annual figure was 621.13%, down 64344.0% from the prior year.
- Operating Margin for Q1 2026 stood at 4834.63%, down from 3249.27% in the prior quarter.
- The five-year high for Operating Margin was 56.42% in Q2 2024, with the low at 4834.63% in Q1 2026.
- The 4-year median for Operating Margin is 89.7% (2023), against an average of 1046.97%.
- The sharpest annual moves came in 2024 and 2026: Operating Margin soared 14612 bps in 2024, then tumbled 472864 bps in 2026.
- Entrada Therapeutics' Operating Margin stood at 11.72% in 2023, then slumped by 234 bps to 15.69% in 2024, then slumped by 20612 bps to 3249.27% in 2025, then sank by 49 bps to 4834.63% in 2026.
- Business Quant data shows TRDA's Operating Margin at 4834.63% in Q1 2026, 3249.27% in Q4 2025, and 2915.18% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | -5,007.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,007.02% |
| Mar 31, 2026 | -4,834.63% |
| Dec 31, 2025 | -3,249.27% |
| Sep 30, 2025 | -2,915.18% |
| Jun 30, 2025 | -2,402.51% |
| Mar 31, 2025 | -105.99% |
| Dec 31, 2024 | -15.69% |
| Sep 30, 2024 | -110.67% |
| Jun 30, 2024 | 56.42% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | 11.72% |
| Sep 30, 2023 | 32.04% |
| Jun 30, 2023 | -89.70% |
| Mar 31, 2023 | -22.88% |